US 12,653,779 · Application 18/239,045 · Granted Jun 16, 2026
US 12,653,779
Compositions and methods for the treatment of presbyopia
Estimated expiration
March 24, 2034
7y 194d remaining
Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.Earliest effective filing
Mar 24, 2014
+ 20 years
Mar 24, 2034
PTA +0d
Mar 24, 2034
No TD
—
Final
Mar 24, 2034
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- August 28, 2023
- Earliest effective filing
- March 24, 2014
- Issue date
- June 16, 2026
- PTA
- 0 days
- Base expiry (before PTA)
- March 24, 2034
March 24, 2014 + 20 years = March 24, 2034
- Continuation of application 17/502,066, filed Oct 15, 2021
- Continuation of application 16/747,070, filed Jan 20, 2020, issued as US 11,179,328
- Divisional of application 16/106,730, filed Aug 21, 2018, issued as US 11,179,327
- Continuation-in-part of application 15/864,703, filed Jan 8, 2018, issued as US 10,617,763
- Continuation-in-part of application 15/235,431, filed Aug 12, 2016, issued as US 10,052,313
- Continuation-in-part of application 15/073,139, filed Mar 17, 2016, issued as US 9,833,441
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation-in-part of application 15/073,089, filed Mar 17, 2016, issued as US 9,844,537
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation-in-part of application 15/073,089, filed Mar 17, 2016, issued as US 9,844,537
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation-in-part of application 15/956,936, filed Apr 19, 2018
- Continuation-in-part of application 15/864,703, filed Jan 8, 2018, issued as US 10,617,763
- Continuation-in-part of application 15/235,431, filed Aug 12, 2016, issued as US 10,052,313
- Continuation-in-part of application 15/073,139, filed Mar 17, 2016, issued as US 9,833,441
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 15/073,089, filed Mar 17, 2016, issued as US 9,844,537
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation-in-part of application 15/235,431, filed Aug 12, 2016, issued as US 10,052,313
- Continuation-in-part of application 15/073,139, filed Mar 17, 2016, issued as US 9,833,441
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 15/073,089, filed Mar 17, 2016, issued as US 9,844,537
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation-in-part of application 15/956,936, filed Apr 19, 2018
- Continuation-in-part of application 15/864,703, filed Jan 8, 2018, issued as US 10,617,763
- Continuation-in-part of application 15/235,431, filed Aug 12, 2016, issued as US 10,052,313
- Continuation-in-part of application 15/073,139, filed Mar 17, 2016, issued as US 9,833,441
- Continuation-in-part of application 15/073,089, filed Mar 17, 2016, issued as US 9,844,537
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Divisional of application 16/106,730, filed Aug 21, 2018, issued as US 11,179,327
- Continuation-in-part of application 15/956,936, filed Apr 19, 2018
- Continuation-in-part of application 15/864,703, filed Jan 8, 2018, issued as US 10,617,763
- Continuation-in-part of application 15/235,431, filed Aug 12, 2016, issued as US 10,052,313
- Continuation-in-part of application 15/073,139, filed Mar 17, 2016, issued as US 9,833,441
- Continuation-in-part of application 15/073,089, filed Mar 17, 2016, issued as US 9,844,537
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- Continuation-in-part of application 14/223,639, filed Mar 24, 2014, issued as US 9,089,562
- Continuation of application 16/747,070, filed Jan 20, 2020, issued as US 11,179,328
- Divisional of application 16/106,730, filed Aug 21, 2018, issued as US 11,179,327
- Continuation-in-part of application 15/956,936, filed Apr 19, 2018
- Continuation-in-part of application 15/864,703, filed Jan 8, 2018, issued as US 10,617,763
- Continuation-in-part of application 15/235,431, filed Aug 12, 2016, issued as US 10,052,313
- Continuation-in-part of application 15/073,139, filed Mar 17, 2016, issued as US 9,833,441
- Continuation-in-part of application 15/073,089, filed Mar 17, 2016, issued as US 9,844,537
- Continuation-in-part of application 14/742,903, filed Jun 18, 2015, issued as US 9,320,709
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
- PRO61/938,438 — Provisional — not used for base term
- PRO61/917,620 — Provisional — not used for base term
- PRO61/904,510 — Provisional — not used for base term
- PRO61/882,998 — Provisional — not used for base term
- PRO61/871,215 — Provisional — not used for base term
Terminal disclaimers
No TD0 approved, 0 filed
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 18/239,045 · US 12,653,779
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,653,779: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12653779Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.